| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2026. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Correspondence |
| Article Title |
Targeting the IGF2BP3/FBXO32/cGMP-PKG axis as a therapeutic modality for gastric cancer: A promising strategy
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Sheng Xu, Zheng Zhu, Pei-Hong Shi, Yue-Ting Xu, Hui-Ming Zhang, Yang Zheng, Yi-Tong Chen, Guang-Rong Lu and Bin-Jiao Zheng |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Zhejiang Medical and Health Science and Technology Plan Project |
2023KY910 |
| Project of Special Research Funds for Clinical Medicine of Zhejiang Medical Association |
2023ZYC-A124 |
|
| Corresponding Author |
Bin-Jiao Zheng, PhD, Key Laboratory of Laboratory Medicine, Ministry of Education, Zhejiang Provincial Key Laboratory of Medical Genetics, School of Laboratory Medicine and Life Sciences, Wenzhou Medical University, University Town, Chashan, Wenzhou 325000, Zhejiang Province, China. gusdy13x@wmu.edu.cn |
| Key Words |
Gastric cancer; N6-methyladenosine; Cyclic guanosine monophosphate-protein kinase G; Molecular markers; IGF2BP3; FBXO32 |
| Core Tip |
Gastric cancer (GC) needs more precise therapies, and Si et al’s study presents promising insights by revealing that the N6-methyladenosine (m6A) reader IGF2BP3 drives GC progression through an m6A-dependent post-transcriptional mechanism. This fills the long-standing gap in understanding the downstream targets of IGF2BP3 in GC and, for the first time, links the IGF2BP3/FBXO32 axis to the cyclic guanosine monophosphate-protein kinase G pathway. Additionally, it promotes discussions on the role of m6A in tumorigenesis and points to critical directions such as mechanistic exploration, tumor microenvironment crosstalk and subtype-specific research, laying key groundwork for translating this axis into GC clinical treatment. |
| Publish Date |
2026-05-26 05:34 |
| Citation |
Xu S, Zhu Z, Shi PH, Xu YT, Zhang HM, Zheng Y, Chen YT, Lu GR, Zheng BJ. Targeting the IGF2BP3/FBXO32/cGMP-PKG axis as a therapeutic modality for gastric cancer: A promising strategy. World J Gastroenterol 2026; 32(21): 116467 |
| URL |
https://www.wjgnet.com/1007-9327/full/v32/i21/116467.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v32.i21.116467 |
